Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2012

View Archived Issues

Novel small molecules target RNA binding site of human DDX3X

Telaprevir improves hepatitis C therapy in HIV-1-coinfected patients

Anti-fibrillogenic agents designed via out-of-plane substitutions show therapeutic potential

Studies demonstrate various therapeutic applications for SEH inhibition

Horizon Discovery and RFUMS to develop human cellular CF model

Recruitment complete in phase II BVT-115959 trial

Mologen seeks approval for study of MGN-1703 in NSCLC

OncoSec begins enrollment at two new sites for metastatic melanoma trial

New P2X4 receptor antagonist is active in models of neuropathic pain

Marina Biotech and ProNAi Therapeutics enter license agreement for DNAi-based therapies

New dipeptide calpain inhibitors reported by Banyan Biomarkers

Enanta presents novel candidate hepatitis C drugs

Novel p53-based peptidomimetics developed at Aileron Therapeutics

Shionogi & Co. divulges novel potential obesity drugs

Novel anti-infectives announced by Novacta Biosystems

Almirall attains new marketing rights to Sativex

Abbott begins phase III studies in hidradenitis suppurativa

Biogen Idec and MAKScientific enter MS agreement

Shire announces planned acquisition

Grifols acquires majority share in Araclon Biotech

Treatment begins in phase III study of CSL Behring's fibrinogen concentrate

Clinuvel provides update on phase III Scenesse trial

Aeras receives grant to develop new vaccines against TB

Thrombogenics and Alcon enter commercialization agreement for ocriplasmin

Novartis withdraws applications for new rivastigmine indication

Repligen commences first-in-human trial of HD inhibitor in Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...